Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
15/08/2023 07:42
Aug 15 (Reuters) -
* FUJI PHARMA - MARKETING APPROVAL FOR GENERIC LENALIDOMIDE,
THE
FIRST COLLABORATION PRODUCT WITH TAIWAN'S LOTUS
Source text: https://www.fujipharma.jp/english/__upload/20230815%20Marketing%20Approval%20for%20generic%20lenalidomide%2C%20first%20collaboration%20products%20with%20Lotus.pdf
Further company coverage: 4554.T 1795.TW
(Reporting by Kantaro Komiya)
((Kantaro.Komiya@thomsonreuters.com;))
Recent news on Lotus Pharmaceutical
See all newsMedia: PTT is said to consider options for Taiwan-listed Lotus Pharma - Bloomberg News
Brief: enz Therapeutics Submits NDA for LNZ100 (Vizz) in South Korea to Treat Presbyopia
Brief: Lotus Pharmaceutical Says Unit Has Closed Deal In Vietnam
Brief: Fuji Pharma: Marketing Approval For Generic Lenalidomide, The First Collaboration Product With Taiwan's Lotus
Brief: Amarin And Lotus Pharmaceuticals Announce Exclusive Partnership In Southeast Asia And South Korea